MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that clinical data for XOPENEX HFA® (levalbuterol tartrate) Inhalation Aerosol and XOPENEX® (levalbuterol HCl) Inhalation Solution will be presented at CHEST 2006, the annual meeting of the American College of Chest Physicians (ACCP), October 21 - 26, 2006 at the Salt Palace Convention Center in Salt Lake City.
